The global Alagille syndrome market is experiencing significant growth driven by rising awareness, advancements in diagnostic tools, and increased adoption of genetic testing. The market's expansion ...

(Nasdaq: MIRM) today announced that on June 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 115,620 ...

The EMA has started a review of GSK's treatment candidate for primary biliary cholangitis (PBC), linerixibat, offering hope ...

GSK plc GSK announced that the European Medicines Agency has accepted its marketing authorization application (MAA) seeking ...

Mirum Pharmaceuticals has demonstrated impressive financial growth over the past year. In 2024, the company’s product revenue reached $336 million, marking an 88% year-over-year increase.

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company specializing in therapies for rare liver diseases, has been making significant strides in the market with its growing product ...

Mirum Pharmaceuticals, Inc. today announced that on June 10, 2025, the Compensation Committee of Mirum’ s Board of Directors granted inducement awards consisting of non-qualified stock options ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on June 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted ...

FOSTER CITY, Calif., June 11, 2025--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on June 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted ...

Mirum Pharmaceuticals is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Moderna (MRNA), a stock from the same industry, has gained 7.1%.

In recent trading activity, Saira Ramasastry, a director at Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a $2.2 billion market cap company that has delivered an impressive 75% return over the past ...